Showing results (331-340 of 1,241) with videos related to

Sort By:
Pageof 125
Journal of Clinical Microbiology|May 8, 2004
mecA Locus diversity in methicillin-resistant Staphylococcus aureus isolates in Brisbane, Australia, and the development of a novel diagnostic procedure for the Western Samoan phage pattern cloneFlavia Huygens, Alex J Stephens, Graeme R Nimmo, et al.
European Journal of Cell Biology|June 25, 2011
A role for Tctex-1 (DYNLT1) in controlling primary cilium lengthKrysten J Palmer, Lucy MacCarthy-Morrogh, Nicola Smyllie, et al.
Plos One|March 28, 2022
Mapping aquifer salinity gradients and effects of oil field produced water disposal using geophysical logs: Elk Hills, Buena Vista and Coles Levee Oil Fields, San Joaquin Valley, CaliforniaJanice M Gillespie, Michael J Stephens, Will Chang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 6, 1999
Identification of residues in the N terminus of alpha1B critical for inhibition of the voltage-dependent calcium channel by Gbeta gammaC Cantí, K M Page, G J Stephens, et al.
Sexually Transmitted Diseases|May 20, 1999
Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor complianceL H Bachmann, J Stephens, C M Richey, et al.
Hospital & Health Services Administration|January 1, 1995
The consequences of disclosure: one hospital's response to the presence of an HIV-positive physicianB J Stephens, P G Sinden, R H Ketcham, et al.
The Journal of Biological Chemistry|May 30, 1997
Serine 331 and tyrosine 333 are both involved in the interaction between the cytosolic domain of TGN38 and the mu2 subunit of the AP2 clathrin adaptor complexD J Stephens, C M Crump, A R Clarke, et al.
The Journal of Biological Chemistry|October 17, 1998
Inhibition of the interaction between tyrosine-based motifs and the medium chain subunit of the AP-2 adaptor complex by specific tyrphostinsC M Crump, J L Williams, D J Stephens, et al.
Molecular Cancer Therapeutics|November 9, 2005
PRL phosphatases as potential molecular targets in cancerBret J Stephens, Haiyong Han, Vijay Gokhale, et al.
British Journal of Cancer|December 1, 1993
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working PartyN M Bleehen, D J Girling, D Machin, et al.
Pageof 125